PMID: 11607931Oct 19, 2001Paper

Tyrosine kinase inhibitors: from rational design to clinical trials

Medicinal Research Reviews
Peter TraxlerJ Zimmermann

Abstract

Protein kinases play a crucial role in signal transduction as well as in cellular proliferation, differentiation, and various regulatory mechanisms. The inhibition of growth related kinases, especially tyrosine kinases, might provide new therapies for diseases such as cancer. The progress made in the crystallization of protein kinases has confirmed that the ATP-binding domain of tyrosine kinases is an attractive target for drug design. Three successful examples of drug design at Novartis using a tyrosine kinase as a molecular target are described. PKI166, a pyrrolo[2,3,-d]pyrimidine derivative, is a dual inhibitor of both the EGFR and the ErbB2 kinases. The compound entered clinical trials in 1999, based on its favorable preclinical profile: potent inhibition of EGF-mediated signalling in cells, in vivo antitumor activity in several EGFR overexpressing xenograft tumor models in nude mice, long-lasting inhibition of EGF-stimulated EGFR autophosphorylation in tumor tissue, good oral bioavailability in animals, and no prohibitive in vitro and in vivo toxicity findings. The anilino-phthalazine derivative PTK787/ZK222584 (Phase I, co-developed by Schering AG, Berlin) is a potent and selective inhibitor of both the KDR and Flt-1 kina...Continue Reading

References

Feb 1, 1993·Current Opinion in Genetics & Development·J Y Wang
Jan 1, 1995·Breast Cancer Research and Treatment·W KolchD Marmé
Mar 28, 1998·Blood Cells, Molecules & Diseases·C Gambacorti-PasseriniN B Lydon
Mar 13, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B R VoldborgH S Poulsen
Jun 20, 1998·Journal of Medicinal Chemistry·S Trumpp-KallmeyerH D Showalter
Nov 5, 1999·Nature Medicine·K Novak
Nov 1, 1993·Trends in Cardiovascular Medicine·N Ferrara

❮ Previous
Next ❯

Citations

Jun 18, 2009·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Keith Ashman, Elena López Villar
Oct 3, 2003·Biochemical and Biophysical Research Communications·Zhen-Dan ShiTerrence R Burke
Apr 15, 2004·Bioorganic & Medicinal Chemistry·Gang ChenHualiang Jiang
Apr 3, 2004·Cancer Treatment Reviews·Sufi Mary Thomas, Jennifer Rubin Grandis
Nov 19, 2003·Journal of Molecular Biology·Stephen A CammerJacquelyn S Fetrow
Apr 23, 2004·Trends in Molecular Medicine·Emanuel F Petricoin, Lance A Liotta
Mar 15, 2003·Clinica Chimica Acta; International Journal of Clinical Chemistry·Monte S Willis, Frank H Wians
Mar 22, 2003·Experimental Cell Research·Thomas HolbroNancy E Hynes
Oct 17, 2002·Journal of Molecular Biology·Lilia M IakouchevaA Keith Dunker
Aug 23, 2002·Pharmacology & Therapeutics·Doriano FabbroPaul W Manley
Jun 1, 2002·Bioorganic & Medicinal Chemistry Letters·Hee-Yoon LeeByoung-Mog Kwon
Jul 20, 2002·Current Opinion in Pharmacology·Doriano FabbroAlex Matter
Sep 27, 2002·Current Opinion in Pharmacology·David H Williams, Tim Mitchell
Oct 4, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Henryk DudekBob D Brown
May 25, 2004·Nature Cell Biology·Romina MaroneAli Badache
Sep 5, 2002·Nature Reviews. Drug Discovery·Emanuel F PetricoinLance A Liotta
Sep 5, 2002·Nature Reviews. Drug Discovery·Patrick Chène
Nov 12, 2005·The New England Journal of Medicine·Ingo K MellinghoffPaul S Mischel
Oct 10, 2003·The New England Journal of Medicine·John M Goldman, Junia V Melo
Apr 3, 2010·The Journal of Biological Chemistry·Allison S Limpert, Bruce D Carter
Sep 18, 2003·Journal of the National Cancer Institute·Catherine A BurkhartMichelle Haber
May 2, 2002·Cancer Nursing·Jennifer T LoudJean Jenkins
Nov 12, 2003·The Journal of Urology·Phillip G Febbo, William R Sellers
Aug 23, 2006·Acta Pharmacologica Sinica·Jian LiHua-liang Jiang
Mar 23, 2004·Annual Review of Immunology·Stephane Wong, Owen N Witte
Sep 12, 2008·Annual Review of Pathology·Michael A Teitell, Pier Paolo Pandolfi
May 5, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Keila E TorresDina Lev
Sep 18, 2004·American Journal of Respiratory and Critical Care Medicine·Aaron A Berlin, Nicholas W Lukacs
Apr 16, 2004·Breast Cancer Research : BCR·Elena Perez-Nadales, Alison C Lloyd
Jan 26, 2010·Marine Drugs·Sébastien DeslandesEvelyne Delfourne
Jun 29, 2011·Future Medicinal Chemistry·Richard J MarhöferPaul M Selzer
Jan 10, 2002·Biochemical and Biophysical Research Communications·Lawrence A SchevingWilliam E Russell
Aug 18, 2004·Proceedings of the National Academy of Sciences of the United States of America·Jeanne A HardyJames A Wells
Jul 11, 2003·Proceedings of the National Academy of Sciences of the United States of America·Thomas HolbroNancy E Hynes
Jul 16, 2005·Pediatric Hematology and Oncology·Soumen Khatua, Rakesh Jalali
Sep 28, 2005·Expert Opinion on Therapeutic Targets·Bert M Klebl, Gerhard Müller
Apr 2, 2003·Expert Opinion on Therapeutic Targets·Peter Traxler
Feb 25, 2003·Expert Review of Anticancer Therapy·Patricia KaaijkGertjan J L Kaspers
Jun 24, 2009·The Journal of Cell Biology·Spiro GetsiosKathleen J Green
May 12, 2015·Expert Opinion on Drug Discovery·Hongyu Zhao, Justin Dietrich

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.